IONS - Ionis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
57.21
-0.23 (-0.40%)
At close: 4:00PM EST

57.21 0.00 (0.00%)
After hours: 6:18PM EST

Stock chart is not supported by your current browser
Previous Close57.44
Open57.54
Bid56.21 x 800
Ask57.99 x 900
Day's Range56.63 - 59.31
52 Week Range39.07 - 59.81
Volume696,548
Avg. Volume998,014
Market Cap7.87B
Beta (3Y Monthly)2.59
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 4 Defensive Stocks to Buy Amid Shutdown and Brexit
    Zacks8 days ago

    4 Defensive Stocks to Buy Amid Shutdown and Brexit

    Defensive equities could ride out market unpredictability.

  • Pfizer Gets FDA's Priority Review for Rare Disease Candidate
    Zacks8 days ago

    Pfizer Gets FDA's Priority Review for Rare Disease Candidate

    FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.

  • This Biotech Stock Plunged On Its Looming Rivalry With Pfizer
    Investor's Business Daily9 days ago

    This Biotech Stock Plunged On Its Looming Rivalry With Pfizer

    Alnylam dipped Monday after the FDA agreed to review an amyloidosis treatment from Pfizer in just six months. Pfizer's drug would treat patients with abnormal protein building in the heart.

  • 3 Top Biotech Stocks to Buy in January
    Motley Fool11 days ago

    3 Top Biotech Stocks to Buy in January

    Adding these biotech stocks to your portfolio could be a great New Year's resolution for aggressive investors.

  • Markit14 days ago

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    # Ionis Pharmaceuticals Inc ### NASDAQ/NGS:IONS View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate ## Bearish sentiment Short interest | Positive Short interest is moderate for IONS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding IONS is favorable, with net inflows of $9.20 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Cannabis, Migraines, Gene-Silencing: FDA Approvals Hit High Note In 2018
    Investor's Business Daily21 days ago

    Cannabis, Migraines, Gene-Silencing: FDA Approvals Hit High Note In 2018

    The Food and Drug Administration approved 59 new drugs in 2018 — hitting at least a four-year record — though fewer biologic drugs passed muster. There were also 17 biologic drugs approved.

  • MoneyShow22 days ago

    Top Picks 2019- Ionis Pharmaceuticals IONS

    Ionis Pharmaceuticals (IONS) is my top pick as a conservative biotech recommendation in 2019; the company represents a unique blend with an exciting and broad pipeline of drug development candidates balanced by revenue generation from approved drugs, observes John McCamant, editor of The Medical Technology Stock Letter.

  • 4 of the Fastest Growing Biotech Stocks in 2019
    Motley Fool23 days ago

    4 of the Fastest Growing Biotech Stocks in 2019

    Earnings per share will more than double for each of these specialty drugmakers.

  • Spectrum Pharmaceuticals: Earnings Trends and Recent Developments
    Market Realist27 days ago

    Spectrum Pharmaceuticals: Earnings Trends and Recent Developments

    In the first nine months of 2018, Spectrum Pharmaceuticals (SPPI) reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively—compared to -$62.7 million and -$0.78 in the same period the previous year.

  • Why Gene Therapy Is More Cost Effective Than Biogen's Approved Drug
    Investor's Business Dailylast month

    Why Gene Therapy Is More Cost Effective Than Biogen's Approved Drug

    An experimental gene therapy from Novartis, called Zolgensma, is more cost effective than Biogen and Ionis Pharmaceuticals' treatment for a muscle-wasting disease, experts said this week.

  • MarketWatchlast month

    Ionis Pharmaceuticals outlines CEO succession plan

    Ionis Pharmaceuticals Inc. said late Thursday that Brett Monia will succeed Stanley Crooke as chief executive in a year. The drug development company said Monia, who is the current chief operating officer, will become CEO in January 2020, and Crooke will become executive chairman of Ionis's board. Shares of Ionis, which were flat after hours, had closed down 2.1% at $49.78 in regular trading Thursday.

  • Do Analysts See Any Upside for Ionis Stock?
    Market Realistlast month

    Do Analysts See Any Upside for Ionis Stock?

    Of the 14 analysts covering Ionis Pharmaceuticals (IONS), five have given it “buy” or higher ratings, seven have given it “holds,” and two have given it “sells.”

  • Understanding Ionis Pharmaceuticals’ Operational Performance
    Market Realistlast month

    Understanding Ionis Pharmaceuticals’ Operational Performance

    In the most recent quarter, Ionis Pharmaceuticals’ (IONS) selling, general, and administrative expenses rose YoY (year-over-year) to $68.71 million from $26.79 million. Meanwhile, its R&D (research and development) expenses rose YoY to $95.25 million from $80.21 million due to higher drug development costs.

  • Taking Stock of Ionis’s Performance
    Market Realistlast month

    Taking Stock of Ionis’s Performance

    Ionis Pharmaceuticals’ (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake. In its Core Ionis segment, the company is using its antisense technology to develop a pipeline of best-in-class drugs.

  • Should You Buy Ionis Pharmaceuticals, Inc. (IONS)?
    Insider Monkeylast month

    Should You Buy Ionis Pharmaceuticals, Inc. (IONS)?

    Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from industry insiders. They sometimes fail miserably but historically their consensus stock picks outperformed the market […]

  • The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
    Zackslast month

    The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

    The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

  • Zackslast month

    Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate

    A low key week for the biotech sector with focus on regular pipeline updates.

  • Simply Wall St.last month

    Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Expensive For A Reason? A Look At The Intrinsic Value

    I am going to run you through how I calculated the intrinsic value of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by estimating the company's future cash flows and discounting them to their Read More...

  • See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    Ionis Pharmaceuticals Inc NASDAQ/NGS:IONS

  • Why Pfizer Could Lead These Two Biotech Stocks In Tackling Amyloidosis
    Investor's Business Daily2 months ago

    Why Pfizer Could Lead These Two Biotech Stocks In Tackling Amyloidosis

    Dow Jones' component Pfizer will take the lion's share of the amyloidosis treatment market — leaving Alnylam and Ionis to duke it out for the remainder, an analyst says.

  • See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    Short interest is moderate for IONS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of IONS earnings conference call or presentation 6-Nov-18 4:30pm GMT

    Q3 2018 Ionis Pharmaceuticals Inc Earnings Call

  • Zacks2 months ago

    Stocks Not in a Bouncy Mood Yet

    Stocks Not in a Bouncy Mood Yet

  • 5 Pharma Stocks to Stay Away From
    InvestorPlace2 months ago

    5 Pharma Stocks to Stay Away From

    Pharma stocks can serve as a profitable addition to investment portfolios. With 10,000 baby boomers aging into Medicare every day, and a Medicare Part D drug plan to subsidize the cost, demographics and government subsidies has created a virtuous cycle for healthcare stocks. As a result, some have seen price levels that its profits (assuming they exist) cannot sustain. Additionally, biotech stocks are inherently risky due to the process of drug development and approval.